Products
Pre-made Lacutamab benchmark antibody ( Whole mAb, anti-KIR3DL2/CD158k therapeutic antibody, Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-290
Pre-Made Lacutamab biosimilar, Whole mAb, Anti-KIR3DL2/CD158k Antibody: Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lacutamab is a humanised version of anti KIR3DL2 monoclonal antibody clone #1, and has been shown to have potent activity against KIR3DL2-positive tumours.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-290-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Lacutamab biosimilar, Whole mAb, Anti-KIR3DL2/CD158k Antibody: Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 therapeutic antibody |
| INN Name | Lacutamab |
| Target | CD158k |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | University of Genoa;Innate Pharma |
| Conditions Approved | na |
| Conditions Active | Mycosis fungoides;Peripheral T-cell lymphoma;Sezary syndrome |
| Conditions Discontinued | na |
| Development Tech | na |
<